
News
Home>News & Events>Publications>CPAD>Apolipoprotein E genotype and sex risk factors for Alzheimer disease
57
Related Posts
-
Effective Data Sharing as a Conduit for Advancing Medical Product Development
-
Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments
-
Concise Informed Consent to Enable Data and Sample Access to Advance Treatments
-
Biometric Monitoring Devices for Objective Assessments of Relevant Endpoints for Clinical Drug Trials: Key Considerations in Developing an Actionable Eco-system
-
Accelerating drug development for Alzheimer’s disease through the use of data standards